The American Journal of Managed Care3d
With Sub-Q Immunotherapy Coming, “Patient Preference Has to Be the Key”
An oncologist from Atrium Health outlines how saving time administering immunotherapy could have far-reaching benefits.
Medscape7d
Tislelizumab Receives First-Line Nod for Unresectable/Metastatic ESCC
The US Food and Drug Administration has approved tislelizumab (Tevimbra, BeiGene), in combination with platinum-containing ...
Bristol-Myers Squibb Company (BMY) Presents at 45th Annual TD Cowen Health Care Conference (Transcript)
Bristol-Myers Squibb Company (NYSE:BMY) 45th Annual TD Cowen Health Care Conference March 4, 2025 2:30 PM ETCompany ParticipantsAdam Lenkowsky - ...
Pharmaceutical Technology15d
FDA accepts BMS’ Opdivo-Yervoy combo sBLA for colorectal cancer
BMS’ Opdivo is approved in more than 65 countries. Credit: Amy Lutz/Shutterstock. The US Food and Drug Administration (FDA) has accepted Bristol Myers Squibb’s (BMS) supplemental biologics licence ...
MarketWatch16d
Bristol Myers Gets Speedy FDA Review of Opdivo/Yervoy Combo in Certain Colorectal Cancer Patients
Bristol Myers Squibb has won Food and Drug Administration priority review for its application seeking approval of the combination of its Opdivo and Yervoy cancer drugs for the early treatment of ...
Business Insider16d
FDA accepts Bristol Myers’ sBLA for Opdivo plus Yervoy
Bristol Myers (BMY) Squibb announced that the U.S. FDA has accepted the supplemental biologics license application for Opdivo plus Yervoy as a potential first-line treatment option for adult and ...
precisionmedicineonline16d
BMS Seeking FDA Approval for Opdivo-Yervoy in Frontline MSI-High, dMMR Advanced Colorectal Cancer
NEW YORK – Bristol Myers Squibb said Monday that the US Food and Drug Administration has accepted its supplemental biologics license application (sBLA) seeking approval for the checkpoint inhibitor ...
Applied Clinical Trials Online19d
ASTRO Trial Shows SC Tremfya Provides Significant Clinical Benefits in Moderately to Severely Active Ulcerative Colitis
Tremfya could become the first IL-23 inhibitor with fully subcutaneous induction and maintenance options in the treatment of ...
PMLiVE19d
BMS shares overall survival results for Opdivo in phase 3 lung cancer trial
The latest results come less than two months after an injectable form of Opdivo was approved by the US Food and Drug Administration for most previously approved adult, solid tumour intravenous (IV) ...
clinicaltrialsarena20d
BMS’ Opdivo plus chemotherapy shows OS benefit in Phase III NSCLC study
Credit: JHVEPhoto / Shutterstock. Bristol Myers Squibb (BMS) has reported outcomes from the Phase III CheckMate -816 trial, indicating an overall survival (OS) benefit when Opdivo (nivolumab) is used ...
Benzinga.com21d
Bristol Myers Cancer Drug Opdivo In Combination With Chemo Shows Improved Overall Survival In Certain Patients With Lung Cancer
Opdivo plus chemotherapy showed a significant overall survival benefit in resectable NSCLC, per final Phase 3 CheckMate -816 study results. In October, the FDA approved Opdivo for resectable NSCLC ...
Hosted on MSN21d
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Q4 2024 Earnings Call Transcript
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Q4 2024 Earnings Call Transcript February 18, 2025 Halozyme Therapeutics, Inc. beats earnings expectations. Reported EPS is $1.26, expectations were $1.17 ...